Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease.
From a total of 81 patients on maintenance hemodialysis who underwent coronary angiography, 8 patients fulfilled the criteria: significant coronary artery disease, hematocrit less than 27%, reproducible (ECG) positive treadmill test, no disturbance of repolarization in ECG at rest. Exercise stress testing was performed at a hematocrit of 25 +/- 2% and following erythropoietin therapy at a hematocrit of 34 +/- 0.5%. Symptom-limited exercise performance increased in all patients (1.10 +/- 0.3 W/kg b.w. vs. 1.44 +/- 0.31 W/kg b.w., p less than 0.01) as well as exercise duration (489 vs. 362 s, p +/- 0.01). ST segment depression during maximal exercise was reduced from a mean of 2.1 to 0.4 mm (p less than 0.01). It is concluded that amelioration of renal anemia by erythropoietin in dialysis patients with significant coronary artery disease reduces exercise-induced myocardial ischemia.
Wizemann
V
V
Georg Haas Dialysis Center, Giessen, FRG.
Kaufmann
J
J
Kramer
W
W
D000328:Adult; D000740:Anemia / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D004921:Erythropoietin / Q000627:therapeutic use*; D015444:Exercise / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006435:Renal Dialysis / Q000009:adverse effects
D004921:Erythropoietin